Mizuho Maintains Outperform on WAVE Life Sciences, Raises Price Target to $27

Mizuho analyst Salim Syed has maintained an Outperform rating on WAVE Life Sciences (NASDAQ: WVE) and raised the price target from $22 to $27. This adjustment reflects a positive outlook for the company's performance in the market.